# A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

> **NCT02583594** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (actual)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Acyclovir
- **DRUG:** Methylprednisolone
- **DRUG:** alemtuzumab GZ402673
- **DRUG:** alemtuzumab GZ402673
- **DRUG:** Paracetamol
- **DRUG:** Loratadine
- **DRUG:** Ceterizine
- **DRUG:** Dexchlorpheniramine

## Key facts

- **NCT ID:** NCT02583594
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-06
- **Primary completion:** 2016-03
- **Final completion:** 2021-03-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583594, "A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02583594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*